Medicine: The Problems And Possibilities Of Peptides
Summary
This 1A Podcast episode examines the booming, loosely regulated market for synthetic peptides, which promise benefits like weight loss and longevity. Host Jen White is joined by Dr. Joshua Sharfstein, Lauren Weber, and Jeff Cohen to discuss a recent FDA advisory panel vote to expand access despite scientists' warnings about insufficient safety data. The panel debates conflicts of interest on the committee, the dangers of the gray market, and whether industry-led standards can replace rigorous federal oversight.
Topics discussed
Intro: Radiolab and the booming peptide market
Defining peptides and the rise of unregulated products
FDA advisory panel vote and political influence
Scientific skepticism and lack of safety data
Conflicts of interest on the FDA advisory panel
Market value vs. public safety concerns
The challenge of testing unowned chemical compounds
Consumer demand driving the gray market
Long-term safety of GLP-1s and historical parallels
How consumers access peptides and regulatory gaps
Consumer responsibility and the need for evidence
Intellectual property hurdles for clinical research
Compounding pharmacies and basement-made vials
Global regulations and the dietary supplement model
Conclusion: Scientific standards and future FDA actions
Listen ad-free on Castria